Esperion Therapeutics, Inc. (ESPR)
After hours:
| Previous close | 2.4300 |
| Open | 2.4600 |
| Bid | 2.3900 x 900 |
| Ask | 2.4400 x 1900 |
| Day's range | 2.3650 - 2.5000 |
| 52-week range | 0.7000 - 3.4000 |
| Volume | |
| Avg. volume | 8,319,330 |
| Market cap | 460.388M |
| Beta (5Y monthly) | 1.02 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.9000 |
| Earnings date | 30 July 2024 - 05 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 7.36 |
GlobeNewswireEsperion to Report Second Quarter 2024 Financial Results on August 12
ANN ARBOR, Mich., July 25, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it will report second quarter 2024 financial results before the market opens on Monday, August 12, 2024. Following the release, management will host a webcast at 8:00 a.m. ET to discuss these financial results and provide business updates. Please click here to pre-register to participate in the conference call and obtain your dial in number and PIN. A live audio webcast can be accessed on the investor and
- GlobeNewswire
Esperion to Participate in Upcoming BTIG Biotech Conference
ANN ARBOR, Mich., July 24, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will be participating in the BTIG Biotech Conference on Monday, August 5, 2024, at 4 p.m. ET. Esperion TherapeuticsAt Esperion, we discover, develop, and commercialize innovative medicines to help improve outcomes for patients with or at risk for cardiovascular and cardiometabolic diseases. The status quo is not meeting the health needs of millions of people with high cholesterol – that i
ZacksAre You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
